This site is AI generated with the help of Leo Capital’s portfolio company - Ronic.ai
Leo Capital
Pitch to us →
Deeptech · Healthtech · USA

Humane Genomics

Humane Genomics

Engineering cancer-killing viruses via a synthetic-biology platform

USADeeptech · Healthtech

About

Humane Genomics is a New York City company developing precision cancer therapies by engineering cancer-killing RNA/oncolytic viruses using a synthetic-biology platform. In February 2025 it announced the close of a Series Seed financing round led by Union Square Ventures. It was founded in 2016 by Peter Weijmarshausen (CEO, formerly co-founder of Shapeways) and Andrew Hessel.

Latest news

Humane Genomics Raises Seed Funding
finsmes.com2025-02
Humane Genomics - Union Square Ventures
usv.com2025-02

Checking the news desk for fresh coverage…

Coverage gathered from public sources.

Why Deeptech

Selective, conviction-led bets at the frontier - quantum, climate and next-generation digital infrastructure - where a technical edge compounds.

Explore the full portfolio →
Pitch to us

Building for the world? We’d love to hear from you.

We read every pitch and respond within 2–3 days. No warm introduction required - a great company can come from anywhere.